United Therapeutics (UTHR) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1-year price objectives for United Therapeutics' stock. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they predict the company's share price to reach $296.44 in the next twelve months. This suggests a possible upside of 33.1% from the stock's current price.
View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts.

United Therapeutics' stock was trading at $278.09 on January 1st, 2023. Since then, UTHR shares have decreased by 19.9% and is now trading at $222.75.
View the best growth stocks for 2023 here.

United Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,090,000 shares, a drop of 42.3% from the August 15th total of 1,890,000 shares. Based on an average daily trading volume, of 332,900 shares, the days-to-cover ratio is presently 3.3 days.
View United Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our UTHR earnings forecast.

United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported $5.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.57 by $0.67. The biotechnology company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $524.18 million. United Therapeutics had a trailing twelve-month return on equity of 17.52% and a net margin of 41.29%. United Therapeutics's quarterly revenue was up 27.8% compared to the same quarter last year. During the same period last year, the company earned $2.41 EPS.

ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Inspire Faithward Mid Cap Momentum ETF (GLRY), Formidable Fortress ETF (KONG), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Intelligent - Large Cap Value ETF (AILV).

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.86%), Renaissance Technologies LLC (4.66%), State Street Corp (4.00%), Geode Capital Management LLC (1.72%), Bank of New York Mellon Corp (1.27%) and Dimensional Fund Advisors LP (1.14%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UTHR stock can currently be purchased for approximately $222.75.

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.45 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $17.68 on an earnings per share basis.

The company employs 985 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.